https://www.evicenter.com/drugs https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/terms-and-abbreviations 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/product-information-and-disease-description 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/clinical-evidence 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/economic-information-and-modeling-report 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/4d-150--neovascular-age-related-macular-degeneration/references 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis 2026-09-21T21:43:18-04:00 https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/terms-and-abbreviations 2026-09-21T21:43:18-04:00 https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/product-information-and-disease-description 2026-09-21T21:43:18-04:00 https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/clinical-evidence 2026-09-21T21:43:18-04:00 https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/economic-information-and-modeling-report 2026-09-21T21:43:18-04:00 https://www.evicenter.com/drugs/anaphylm--type-i-allergic-reactions-including-anaphylaxis/references 2026-09-21T21:43:18-04:00 https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia 2026-10-02T18:22:10-04:00 https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/terms-and-abbreviations 2026-10-02T18:22:10-04:00 https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/product-information-and-disease-description 2026-10-02T18:22:10-04:00 https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/clinical-evidence 2026-10-02T18:22:10-04:00 https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/economic-information-and-modeling-report 2026-10-02T18:22:10-04:00 https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/references 2026-10-02T18:22:10-04:00 https://www.evicenter.com/drugs/aqneursa--ataxia-telangiectasia/monograph/review 2026-10-02T18:22:10-04:00 https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva 2026-10-01T20:09:36-04:00 https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/terms-and-abbreviations 2026-10-01T20:09:36-04:00 https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/product-information-and-disease-description 2026-10-01T20:09:36-04:00 https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/clinical-evidence 2026-10-01T20:09:36-04:00 https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/economic-information-and-modeling-report 2026-10-01T20:09:36-04:00 https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/references 2026-10-01T20:09:36-04:00 https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/monograph/review 2026-10-01T20:09:36-04:00 https://www.evicenter.com/drugs/atebrioz--fibrodysplasia-ossificans-progressiva/budget-impact 2026-10-01T20:09:36-04:00 https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration/terms-and-abbreviations 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration/product-information-and-disease-description 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration/clinical-evidence 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration/economic-information-and-modeling-report 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/axpaxli--neovascular-age-related-macular-degeneration/references 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures 2026-09-21T21:41:53-04:00 https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/terms-and-abbreviations 2026-09-21T21:41:53-04:00 https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/product-information-and-disease-description 2026-09-21T21:41:53-04:00 https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/clinical-evidence 2026-09-21T21:41:53-04:00 https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/economic-information-and-modeling-report 2026-09-21T21:41:53-04:00 https://www.evicenter.com/drugs/azetukalner--focal-onset-seizures/references 2026-09-21T21:41:53-04:00 https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/terms-and-abbreviations 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/product-information-and-disease-description 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/clinical-evidence 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/economic-information-and-modeling-report 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/bezuclastinib--gastrointestinal-stromal-tumor/references 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis 2026-09-17T22:01:26-04:00 https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/terms-and-abbreviations 2026-09-17T22:01:26-04:00 https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/product-information-and-disease-description 2026-09-17T22:01:26-04:00 https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/clinical-evidence 2026-09-17T22:01:26-04:00 https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/economic-information-and-modeling-report 2026-09-17T22:01:26-04:00 https://www.evicenter.com/drugs/bezuclastinib--nonadvanced-systemic-mastocytosis/references 2026-09-17T22:01:26-04:00 https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension/terms-and-abbreviations 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension/product-information-and-disease-description 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension/clinical-evidence 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension/economic-information-and-modeling-report 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/bim-iol-system--open-angle-glaucoma-or-ocular-hypertension/references 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/cytisinicline--smoking-cessation 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/terms-and-abbreviations 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/product-information-and-disease-description 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/clinical-evidence 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/economic-information-and-modeling-report 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/cytisinicline--smoking-cessation/references 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/terms-and-abbreviations 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/product-information-and-disease-description 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/clinical-evidence 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/economic-information-and-modeling-report 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/deramiocel--duchenne-muscular-dystrophy/references 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria 2026-09-21T21:42:40-04:00 https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/terms-and-abbreviations 2026-09-21T21:42:40-04:00 https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/product-information-and-disease-description 2026-09-21T21:42:40-04:00 https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/clinical-evidence 2026-09-21T21:42:40-04:00 https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/economic-information-and-modeling-report 2026-09-21T21:42:40-04:00 https://www.evicenter.com/drugs/dersimelagon--erythropoietic-protoporphyria-or-x-linked-protoporphyria/references 2026-09-21T21:42:40-04:00 https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/terms-and-abbreviations 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/product-information-and-disease-description 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/clinical-evidence 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/economic-information-and-modeling-report 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/duravyu--wet-age-related-macular-degeneration/references 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/emcitate--mct8-deficiency 2026-09-29T17:13:11-04:00 https://www.evicenter.com/drugs/emcitate--mct8-deficiency/terms-and-abbreviations 2026-09-29T17:13:11-04:00 https://www.evicenter.com/drugs/emcitate--mct8-deficiency/product-information-and-disease-description 2026-09-29T17:13:11-04:00 https://www.evicenter.com/drugs/emcitate--mct8-deficiency/clinical-evidence 2026-09-29T17:13:11-04:00 https://www.evicenter.com/drugs/emcitate--mct8-deficiency/economic-information-and-modeling-report 2026-09-29T17:13:11-04:00 https://www.evicenter.com/drugs/emcitate--mct8-deficiency/references 2026-09-29T17:13:11-04:00 https://www.evicenter.com/drugs/emcitate--mct8-deficiency/monograph/review 2026-09-29T17:13:11-04:00 https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/terms-and-abbreviations 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/product-information-and-disease-description 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/clinical-evidence 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/economic-information-and-modeling-report 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/emiltatug-ledadotin--adenoid-cystic-carcinoma-with-solid-histology-or-high-grade-transformation/references 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/terms-and-abbreviations 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/product-information-and-disease-description 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/clinical-evidence 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/economic-information-and-modeling-report 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/imlifidase--kidney-transplantation-in-highly-sensitized-patients/references 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/terms-and-abbreviations 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/product-information-and-disease-description 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/clinical-evidence 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/economic-information-and-modeling-report 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/imsidolimab--generalized-pustular-psoriasis/references 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/terms-and-abbreviations 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/product-information-and-disease-description 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/clinical-evidence 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/economic-information-and-modeling-report 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/ivonescimab--egfr-mutated-non-small-cell-lung-cancer/references 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/juvmo--parkinson-s-disease 2026-10-01T20:10:19-04:00 https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/terms-and-abbreviations 2026-10-01T20:10:19-04:00 https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/product-information-and-disease-description 2026-10-01T20:10:19-04:00 https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/clinical-evidence 2026-10-01T20:10:19-04:00 https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/economic-information-and-modeling-report 2026-10-01T20:10:19-04:00 https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/references 2026-10-01T20:10:19-04:00 https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/monograph/review 2026-10-01T20:10:19-04:00 https://www.evicenter.com/drugs/juvmo--parkinson-s-disease/budget-impact 2026-10-01T20:10:19-04:00 https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma 2026-10-01T20:01:05-04:00 https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/terms-and-abbreviations 2026-10-01T20:01:05-04:00 https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/product-information-and-disease-description 2026-10-01T20:01:05-04:00 https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/clinical-evidence 2026-10-01T20:01:05-04:00 https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/economic-information-and-modeling-report 2026-10-01T20:01:05-04:00 https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/references 2026-10-01T20:01:05-04:00 https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/monograph/review 2026-10-01T20:01:05-04:00 https://www.evicenter.com/drugs/lirafugratinib--previously-treated-fgfr2-fusion-or-rearrangement-positive-cholangiocarcinoma/budget-impact 2026-10-01T20:01:05-04:00 https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/terms-and-abbreviations 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/product-information-and-disease-description 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/clinical-evidence 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/economic-information-and-modeling-report 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/lonvoguran-ziclumeran--hereditary-angioedema/references 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration 2026-09-28T12:24:10-04:00 https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/terms-and-abbreviations 2026-09-28T12:24:10-04:00 https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/product-information-and-disease-description 2026-09-28T12:24:10-04:00 https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/clinical-evidence 2026-09-28T12:24:10-04:00 https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/economic-information-and-modeling-report 2026-09-28T12:24:10-04:00 https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/references 2026-09-28T12:24:10-04:00 https://www.evicenter.com/drugs/lytenava--neovascular-age-related-macular-degeneration/monograph/review 2026-09-28T12:24:10-04:00 https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/terms-and-abbreviations 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/product-information-and-disease-description 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/clinical-evidence 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/economic-information-and-modeling-report 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/molgramostim-inhalation-solution--autoimmune-pulmonary-alveolar-proteinosis/references 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/terms-and-abbreviations 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/product-information-and-disease-description 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/clinical-evidence 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/economic-information-and-modeling-report 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/qtorin-rapamycin-3-9-percent-gel--microcystic-lymphatic-malformations/references 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/terms-and-abbreviations 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/product-information-and-disease-description 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/clinical-evidence 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/economic-information-and-modeling-report 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/references 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/terms-and-abbreviations 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/product-information-and-disease-description 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/clinical-evidence 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/economic-information-and-modeling-report 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/saroglitazar--primary-biliary-cholangitis/references 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/sky-0515--huntington-s-disease 2026-10-01T20:05:00-04:00 https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/terms-and-abbreviations 2026-10-01T20:05:00-04:00 https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/product-information-and-disease-description 2026-10-01T20:05:00-04:00 https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/clinical-evidence 2026-10-01T20:05:00-04:00 https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/economic-information-and-modeling-report 2026-10-01T20:05:00-04:00 https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/references 2026-10-01T20:05:00-04:00 https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/monograph 2026-10-01T20:05:00-04:00 https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/budget-impact 2026-10-01T20:05:00-04:00 https://www.evicenter.com/drugs/sky-0515--huntington-s-disease/model 2026-10-01T20:05:00-04:00 https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/terms-and-abbreviations 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/product-information-and-disease-description 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/clinical-evidence 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/economic-information-and-modeling-report 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/sl1009--pyruvate-dehydrogenase-complex-deficiency/references 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/terms-and-abbreviations 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/product-information-and-disease-description 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/clinical-evidence 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/economic-information-and-modeling-report 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/tinlarebant--stargardt-disease-type-1/references 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/terms-and-abbreviations 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/product-information-and-disease-description 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/clinical-evidence 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/economic-information-and-modeling-report 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/tirabrutinib--primary-central-nervous-system-lymphoma/references 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer 2026-09-21T22:15:09-04:00 https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/terms-and-abbreviations 2026-09-21T22:15:09-04:00 https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/product-information-and-disease-description 2026-09-21T22:15:09-04:00 https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/clinical-evidence 2026-09-21T22:15:09-04:00 https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/economic-information-and-modeling-report 2026-09-21T22:15:09-04:00 https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/references 2026-09-21T22:15:09-04:00 https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/monograph 2026-09-21T22:15:09-04:00 https://www.evicenter.com/drugs/tovecimig--second-line-advanced-biliary-tract-cancer/monograph/oregon 2026-09-21T22:15:09-04:00 https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/terms-and-abbreviations 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/product-information-and-disease-description 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/clinical-evidence 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/economic-information-and-modeling-report 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/tovorafenib--raf-altered-pediatric-low-grade-glioma-requiring-first-line-systemic-therapy/references 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/terms-and-abbreviations 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/product-information-and-disease-description 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/clinical-evidence 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/economic-information-and-modeling-report 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/ulixacaltamide--essential-tremor/references 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/terms-and-abbreviations 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/product-information-and-disease-description 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/clinical-evidence 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/economic-information-and-modeling-report 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/zanzalintinib--metastatic-colorectal-cancer/references 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/terms-and-abbreviations 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/product-information-and-disease-description 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/clinical-evidence 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/economic-information-and-modeling-report 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/zeleciment-rostudirsen--duchenne-muscular-dystrophy/references 2026-09-19T05:27:14-04:00 https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/terms-and-abbreviations 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/product-information-and-disease-description 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/clinical-evidence 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/economic-information-and-modeling-report 2026-09-19T11:14:25-04:00 https://www.evicenter.com/drugs/zipalertinib--egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/references 2026-09-19T11:14:25-04:00 https://www.evicenter.com/p-and-t-committee-meetings